From Lab to Clinic: The Drug Development Pipeline

Drug development begins with a biological hypothesis: that interfering with a specific molecular target will produce a therapeutic effect in humans. The early discovery phase is where researchers identify candidate compounds or biologics — proteins, antibodies, small molecules — that interact with the target in the intended way. This phase happens almost entirely in cell cultures and computer models, and it is less a pipeline than a filter. Of every ten thousand compounds screened in early discovery, roughly one will eventually enter human trials.

Target validation is the first serious decision gate in the pipeline. Researchers must demonstrate not only that the target exists and is modifiable, but that modifying it actually produces the desired biological outcome. A target can be real and druggable and still be the wrong target — because the pathway it sits in compensates, or because the disease in humans involves mechanisms the animal model does not replicate. Target validation failures are the most expensive kind because they invalidate the entire hypothesis, not just one compound.

Preclinical development is the stage where candidate compounds are tested in cell-based assays and animal models to generate enough safety and efficacy data to justify exposing a human to the drug. The FDA requires preclinical data before approving an Investigational New Drug application, or IND, which is the regulatory authorization to begin human testing. Preclinical work typically takes three to six years and costs tens of millions of dollars before the first patient is enrolled. The IND application itself is a regulatory threshold, not a guarantee — the FDA has thirty days to object, and silence constitutes approval.

The gap between preclinical results and human results is where most drug development money disappears. Animal models are imperfect surrogates for human biology. A compound that eliminates a tumor in mice may be metabolized differently in humans, may not achieve therapeutic concentration in the target tissue, or may produce toxicity that animal studies did not predict. The translation gap is not a failure of scientific rigor — it is a structural feature of biological complexity. Every pipeline projection that assumes preclinical success predicts clinical success is ignoring the base rate.

Biologics and small molecules follow similar regulatory pathways but have meaningfully different development profiles. Small molecules are chemically synthesized, typically taken orally, and can often be manufactured at scale with established chemistry processes. Biologics — including monoclonal antibodies, gene therapies, and cell therapies — are derived from living systems, are usually administered by injection or infusion, and have manufacturing processes so complex that the manufacturing process is considered part of the product itself. A change in how a biologic is made can require new clinical data to demonstrate the product is still the same.

The full drug development timeline from initial discovery to FDA approval averages ten to fifteen years when measured across approved drugs. This number is almost always quoted optimistically in pitch decks because it describes the path that succeeded. The drugs that failed at each stage — and ninety percent of candidates that enter clinical trials do fail — consumed years and capital without generating that timeline. Founders evaluating biotech investments or partnerships need to hold both numbers simultaneously: the timeline to approval if it works, and the probability that it works at all.